U.S. markets close in 4 hours 39 minutes

Inari Medical, Inc. (NARI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
82.75+0.60 (+0.73%)
As of 11:19AM EDT. Market open.
Sign in to post a message.
  • A
    Anonymous
    i get why financials might be down, or industrial materials, even consumer discretionary, but why is NARI down? how does a medical, sound company like NARI have any exposure to Chinese housing?
  • A
    Anonymous
    what i got out of conference call today:
    "a very different company 12-18 months from now"
    finance guy made more than a commendable effort in trying to find out what that meant, but NARI guys would not elaborate... but the question that i think may have revealed something was "organic/inorganic?" and NARI guy only took it as "are we acquiring someone?" and commented along the lines of "there's nothing imminent". My take: complete head fake. I think they might be a target...

    trials all going great, even an independent Buckley Study(?), 60% of customers being called upon are using/going to use technology, patent for Flowtriever 2, stream of new products (no reveals), have 200 sales reps/1100 customers, targeting 350-400 reps and 2000 viable customers that have cath labs.

    otherwise notable, commenting along the lines of competition:
    they (Walk and DeVoro) actually help in marketing the acceptance of this technology and no plan to lower price, see no pricing pressures but since our margins "start with the number 9", if we see we have to then we have a great place to start from.
    Bullish
  • A
    Anonymous
    what i got out of the call:
    procedure is super safe, super effective above anything else.
    replenishment product pipeline seems stable and established, increased due to new product introductions.
    european foothold established, especially in western europe.
    a pipeline of tangential new products can be expected to be released Q4 through the 1H of next year, in addition to flowsaver.
    TAM related to Covid induced clots was 11% in Q2 and decreasing from Q1, down to 4% recently, yet total TAM increased...
    which means (unfortunately) the significant Q3 spike we're seeing in Covid now is going to be on top of the increase in "normal"/target (non-Covid) procedures.
    Bullish
  • A
    Anonymous
    YES!
    revenue growing triple digits, topped the range of expectations, 2.5x YoY.
    increased margins
    increased guidance outlook
    FDA approval granted on new product

    ... I'll hold. I know it shouldn't be a CPI dependent stock, but the way i've been timing sales and buys, i'll just hold this one for a while...
    Bullish
  • D
    Dragan
    Numbers are very good, future is even better......
  • A
    Abulurd
    They post good numbers, that doesn't mean anything, stock goes down.
  • b
    bennett
    This stock has clearly become a momentum play based on its roller coaster moves!
  • A
    Anonymous
    finally got a chance to watch the Morgan Stanley conference call posted.. what I got out of it:
    - not much change from last conference call a week ago
    - covid update: a non-covid environment would definitely provide more access to doctors and adoption but this last covid wave is providing another "tailwind" of procedures and awareness into the technology
    - see themselves in a "fantastic spot post-covid"
    - flowsaver was highly anticipated product launch, huge demand, 1000 procedures in just first month of introduction
    - claim to be best in class, blood-less procedure
    - operating in the black, not consuming cash
    - concentrating on growth, not profit (i don't know if i like them saying that all the time... why not both!?)
    Bullish
  • A
    Anonymous
    I don't get the fuss about covid revenue...
    3Q20 - 38.72 11%?(covid related) 4.26(covid revenue)
    4Q20 - 48.61 20%?(guess) 9.72
    1Q21 - 57.40 20%(stated) 11.48
    2Q21 - 63.45 11%(stated) 6.98

    I don't think we got numbers of covid revenue as a percentage for Q3 and 4 of 20, but if you search coronavirus on google and hit statistics, there's a nice graph I'm making assumptions off of. The curve of Q3/4 going up almost exactly mirrors Q1/2 going down so, assuming these same covid patient percentages, i listed covid revenue in that last column. There are arguments for lower and higher covid percentages:
    - doctors less likely in early covid/early NARI to treat covid victims
    - delay between covid recording and clot treatment recording
    - or... last resort, might as well try (?)

    In any case, the resultant non-covid revenues (just straight percentages) ends up:
    3Q20 - 34.46
    4Q20 - 38.89 12.85%
    1Q21 - 45.92 18.08%
    2Q21 - 56.47 22.97% QoQ non-covid increases! ... in a covid environment! where's the slowing down? are my numbers all wrong? so, i don't get this last dip at all. The expenses were all investment, not significant or out of line. I'm more worried about next quarter's dip,
    increasing expenses: more sales people selling in a covid environment, higher R&D on a "stream" of new products, more regulatory filings and regulatory, efficacy and safety studies to conduct. They went from calling on 1000 to 1100 customers. ...On the other hand, even if non-covid revenues increase at the lowest percentage in the year, they've already exceeded last quarter's revenue (above guidance) and I think we can count on another 11%+ covid pop quarter. news on new products being introduced, and huge world market expansion (they're just over 5% of TAM, h u g e room to grow)...
  • A
    Anonymous
    this stock has been so beat up this past quarter, that if NARI posts anything close to or exceeding expectations on ER, I think this will pop $34 next week...
    Bullish
  • K
    K B B
    This will be either 95 or 83 after hours. Unless revenues are growing triple digits, good earnings are getting sold on news. I sold half yesterday at 94. I might sell the rest today if this go back up to 92 before the closing bell. CPI numbers coming out tomorrow. Bad numbers are expected. How bad is the question. Everything is so expensive now especially gas, food, restaurants, hotels, airfare and even Uber.
  • S
    Saison17
    Needs to drop another 50% before I’ll buy.
  • K
    K B B
    missed earnings. 10 cents expected but came in at 8 cents. P/S over 20 still at $80 pps. Too late to sell but looking to average down when it finds a bottom
  • Y
    Yahoo Finance Insights
    Inari Medical is down 6.22% to 84.13
  • Y
    Yahoo Finance Insights
    Inari Medical is down 5.92% to 89.62
  • Y
    Yahoo Finance Insights
    Inari Medical is down 12.25% to 78.02
  • T
    Tommy
    I told you, peak business. Holy Saul was Right too! It's a sell now and won't ever see a new ATH here
    Bearish
  • Y
    Yahoo Finance Insights
    Inari Medical is up 5.58% to 91.97